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Summary
In this paper we derive the joint distribution of progression-free and overall survival
as a function of transition probabilities in a multistate model. No assumptions on
copulae or latent event times are needed and the model is allowed to be non-Markov.
From the joint distribution, statistics of interest can then be computed. As an example,
we provide closed formulas and statistical inference for Pearson’s correlation coef-
ficient between progression-free and overall survival in a parametric framework.
The example is inspired by recent approaches to quantify the dependence between
progression-free survival, a common primary outcome in phase III trials in oncol-
ogy, and overall survival. We complement these approaches by providing methods
of statistical inference while at the same time working within a much more parsimo-
nious modelling framework. Our approach is completely general and can be applied
to other measures of dependence. We also discuss extensions to nonparametric infer-
ence. Our analytical results are illustrated using a large randomized clinical trial in
breast cancer.
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1 INTRODUCTION
An establishedway to evaluate performance of therapies in clinical trials are time-to-event endpoints.While overall survival (OS)
remains the gold standard for demonstrating clinical benefit, especially in oncology, alternative endpoints such as progression-
free survival (PFS), are also accepted by Health Authorities1,2. PFS is not only considered a surrogate for OS, but may provide
clinical benefit by itself, e.g. by delaying symptoms or subsequent therapies3. Further advantages of the use of PFS are shorter
trial durations and the fact that, as opposed to OS, PFS is not confounded by the use of later line, i.e. post-progression, therapies,
and PFS is less vulnerable to competing causes of death than OS4.
Methodology has been developed to assess surrogacy of one endpoint for another5 and these methodologies have been applied
to a wide range of indications6. One important aspect in the assessment of surrogacy is to quantify the correlation between
the surrogate and the real endpoint7. This aspect has received quite some attention in the literature lately8,9. These two papers
consider Pearson’s correlation coefficient and rely on an illness-death model without recovery (IDM) to model the association
between PFS and OS. To specify the underlying statistical model for the likelihood function for parametric estimation, they use
a latent failure time approach. One characteristic of the latent failure time approach is that it allows for PFS events after OS, see
Section 2.3.Within this model formulation, Fleischer et al.8 then derive closed formulas for the survival functions푆푃퐹푆 and푆푂푆
for PFS and OS as well as the correlation coefficient Corr(PFS,OS) by assuming an exponential distribution for all transition
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intensities in the underlying multistate model. Li and Zhang9 generalized these results to Weibull transition intensities, where
closed formulas are provided imposing the assumption of equal Weibull shape parameter for all three transition intensities.
Notably, while in Fleischer et al.8 and Li and Zhang9 point estimates are provided for the quantities of interest based on the
made parametric assumptions, they do not provide a discussion of statistical inference, e.g. how to derive pointwise confidence
intervals for the distribution functions at a milestone time or for the correlation coefficient directly. We further discuss the
contributions of these papers in detail in Section 4. One aim of this paper is to provide for such methods of statistical inference
while ensuring that PFS does not exceed OS.
Finally, in a Bayesian framework the joint distribution of PFS andOS can bemodelled based on aGaussian copula10. Inference
is based on a likelihood function that relies on the latent failure time approach, i.e. derives each patient’s contribution to the
likelihood based on his or her censoring pattern.
We extend the existing body of work in multiple directions. To begin, we model PFS and OS as arising from an IDM without
recovery. The only assumption will be that the model is smooth in the sense that transition intensities between all states of the
model exist. No assumption about latent times or copulas will be made and the model is allowed to be non-Markov. Because the
transition probabilities provide a full description of the IDM, we first recollect closed formulas for the transition probabilities in
an IDM process 푋, following Hougaard11. We derive these probabilities for 푋 a general, not necessarily Markov, process. The
implication of푋 being non-Markov for the considered IDM is that the hazard for the transition from the diseased into the death
state, 훼12(푡; 푡1), will depend on the time 푡 since time origin and on the time 푡1 of entry into the diseased state. While conceptually
offering more modelling flexibility, this generalization complicates derivation of closed formulas for the quantities of interest,
since one additionally needs to integrate out over the distribution of 푡1. There are multiple ways how 훼12(푡; 푡1) can depend on
푡1, e.g. as function of 푡 and 푡1 separately or via the duration 푡 − 푡1 only. Naming of these specific assumptions has not been
unambiguously in the literature and we provide a discussion of the terminology.
Based on the transition probabilities, we derive closed formulas not only for 푆푃퐹푆 , 푆푂푆 , and Corr(PFS,OS), but also for
the joint distribution of PFS and OS. It is worth noting that the latter entirely specifies the association between PFS and OS
based on the assumed IDM model alone, i.e. without having to make additional assumptions, e.g. about a copula function as in
Burzykowski et al.5. For all these quantities, and under parametric assumptions on the transition hazards, statistical inference
can be performed either via standard likelihood theory together with the 훿-rule or bootstrap for parametric models. Note that,
unlike in Li and Zhang9, with the IDM formulation there is no need to restrict the Weibull shape parameter to coincide between
all three transition intensities.
There is a rich theory allowing for nonparametric estimation of transition hazards and subsequently probabilities, see e.g.
Hougaard11 or Aalen et al.12. Through simple plug-in of these estimates we also get nonparametric estimates for the above
quantities, thereby extending the existing purely parametric approaches8,9. Inference for these models is possible via bootstrap.
Estimating transition probabilities nonparametrically based on possibly right-censored data adds one complication though: to
estimate a correlation coefficient we rely on expectations and variances with respect to 푆푃퐹푆 and 푆푂푆 , i.e. we either need
estimates of these survival functions down to 0 or we restrict estimation of expectations to some maximum time.
It is well-known that the latent failure formulation of competing risk or multistate models in general suffers from identifiabil-
ity and interpretability issues. We discuss these in more detail and shed some light on how the latent times, if they are introduced,
relate to the transition hazards from an IDM. In contrast to using latent times, copulas may be applied to modelling the depen-
dence of PFS and OS without assuming such a latent structure. However, typical copula models consider the dependence of
general multivariate survival times, such as the lifetimes of twins, and neither allow for PFS = OS with positive probability nor
ensure the natural PFS ≤ OS. These two aspects are accounted for in a multistate model, which makes the latter framework a
natural choice for joint modelling of PFS and OS.
Lately,Weber and Titman13 also pointed out the mentioned deficiencies of copulas and the latent-failure timemodel used in8,9
to model the association between PFS and OS. They also advocate an IDM, but, in contrast to our paper, focus on demonstrating
the shortcomings of copula modelling for PFS and OS using Kendall’s 휏, also using the likelihood approach of Li and Zhang9.
Wewould like to emphasize that our results are neither specific to themodelling of PFS andOS in oncology nor to investigating
their correlation as one choice of measuring dependence, but are applicable to any IDM.
In Section 2 we introduce amultistate model that allows to explicitly derive the joint distribution of PFS andOS under virtually
no assumptions and we show how this can be used to derive a formula for Pearson’s correlation coefficient. Furthermore, we
outline that patient trajectories for PFS and OS from our model can easily be simulated. Section 3 revisits existing approaches
using the latent failure time approach and discusses how our proposal allows to extend these methods using more parsimonious
assumptions. How tomake inference in our proposed setup is described in Section 4 while Section 5 reports on a small simulation
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study for the correlation coefficient; additional simulation results are provided in the online supplement. In Section 6 we then
illustrate the developed methodology using a large Phase 3 randomized oncology clinical trial and compare it to previously
proposed approaches. We conclude with a discussion in Section 7.
2 A MULTISTATE MODEL FOR PFS AND OS
We introduce the general model in Section 2.1 along with an algorithm to generate data from the model, which can, e.g., be
used for numerical approximations. The model may or may not be time-inhomogeneous Markov, and violations of the Markov
assumption are summarized in Section 2.2. Section 2.3 discusses advantages of our approach over latent failure time and over
copula modelling. We also discuss how to derive the model specification within a latent times approach as in Fleischer et
al.8 and Li and Zhang9 based on our more parsimonious model. Both transition probabilities of the multistate model and the
joint distribution of PFS and OS are in Section 2.4. Based on the joint distribution, dependency measures of PFS and OS can
be expressed, and we exemplarily consider the correlation in Section 2.5. We reiterate that our derivations hold for a general
IDM without recovery. The model is not required to be Markov, the transition intensities may be time-dependent and their
parametric specificationmay depart from those in Fleischer et al.8 and Li and Zhang9. Dependencemeasures other than Pearson’s
correlation coefficient can be expressed, e.g. transition intensities can be plugged into (10) in Weber and Titman13 to receive
Kendall’s 휏.
2.1 The general model and generation of PFS-OS trajectories
We jointly model progression and death in an ‘illness-death’ multistate model14,15. The model is illustrated in Figure 1 .
0Initial
α02(t)
1
Progression
α12(t; t1)α01(t)
2 Death
FIGURE1 Multistate model for PFS andOS: PFS is the waiting time in the initial state 0, OS is the waiting time until absorption
in state 2.
Let 푋(푡) denote the state occupied at time 푡, 푡 ≥ 0, 푋(푡) ∈  ∶= {0, 1, 2}. We assume that all individuals are in the initial
state 0 at time 0, 푃 (푋(0) = 0) = 1, typically upon randomization to treatment. At the time of diagnosis of progression, patients
make a 0 → 1 transition, and subsequent death is modelled as a 1 → 2 transition. Patients who die without prior progression
diagnosis make a direct 0 → 2 transition into the absorbing state. Progression-free survival is the waiting time in the initial
state 0,
PFS = inf{푡 ∶ 푋(푡) ≠ 0},
and overall survival is the time until reaching the death state 2,
OS = inf{푡 ∶ 푋(푡) = 2}.
Patients with a diagnosed progression have PFS < OS, while patients who make a direct 0 → 2 transition have PFS = OS. At
this stage, it is important to note that no assumption about any dependence or independence of PFS and OS has entered so far,
other than the natural PFS ≤ OS. That is, the only assumption we have made so far is that there is no progression after death.
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We will assume that the multistate model is sufficiently smooth in that the following intensities exist,
훼0푗(푡) = limΔ푡↘0
푃 (PFS ∈ [푡, 푡 + Δ푡), 푋(PFS) = 푗 |PFS ≥ 푡)
Δ푡
, 푗 = 1, 2, (1)
and, for 푡1 < 푡,
훼12(푡; 푡1) = limΔ푡↘0
푃 (푋(푡 + Δ푡) = 2 |푋(푡−) = 1,PFS = 푡1)
Δ푡
(2)
= lim
Δ푡↘0
푃 (OS − PFS ∈ [푡 − 푡1, 푡 − 푡1 + Δ푡) |OS ≥ 푡,PFS = 푡1)
Δ푡
.
These definitions are generally valid, also for 푋(푡) a non-Markov process. In Section 2.2 we discuss the classification of
assumptions on 푋 and the implications for the definition of 훼12 in more detail.
The waiting times in the initial state and in the intermediate state in the model of Figure 1 have survival distributions
푆푃퐹푆(푡) = 푃 (PFS > 푡) = exp
⎛⎜⎜⎝−
푡
∫
0
훼01(푢) + 훼02(푢) d푢
⎞⎟⎟⎠ (3)
and, conditional on progression at time 푡1,
푃 (OS − PFS > 푣 |PFS = 푡1 < OS) = exp ⎛⎜⎜⎝−
푡1+푣
∫
푡1
훼12(푢; 푡1) d푢
⎞⎟⎟⎠ . (4)
Noting that PFS < OS given PFS = 푡1 with probability 훼01(푡1)∕(훼01(푡1) + 훼02(푡1))16, these formulae can be used to simulate
PFS-OS-trajectories15 without resorting to latent times. One first simulates a PFS time using Equation (3), say PFS = 푡1. In a
second step, one decides on PFS < OS, if a binomial experiment with ‘success’ probability 훼01(푡1)∕(훼01(푡1) + 훼02(푡1)) yields
‘success’. In this case, the residual time until OS is simulated fromEquation (4). Otherwise, PFS = OS. This simulation approach
is advantageous for numerical approximations. Below, we will find that some expressions may be rather tedious in the general
non-Markov case, but they may be simply approximated by their empirical counterparts after having generated a large number
of trajectories.
2.2 Assumptions for non-Markov models
In a non-Markov IDM, i.e., without the possibility of 1 → 0 transitions, and common initial state 0, the 1 → 2 hazard 훼12(푡; 푡1)
will depend on time 푡 since time origin and on time 푡1 of entry into state 1, see Chapter 5 in Hougaard11 or Chapter 12 in
Beyersmann et al.15. Since all transitions other than 1→ 2, i.e. 0→ 1 and 0→ 2, are rooted in 0, making the transition intensity
훼12(푡; 푡1) depend on 푡1 summarizes the entire “past” prior to the 1→ 2 transition.
Now, classification of non-Markovmodels does not seem to be entirely consistent in the literature. Amodel for which 훼12(푡; 푡1)
depends only on the time since progression, 훼12(푡; 푡1) = 훼12(푡 − 푡1) for all 푡1 < 푡, goes by the name semi-Markov in Hougaard
(Table 6.1)11 and Beyersmann et al. (p. 229)15, or clock reset in Putter et al.17. The latter refers to the fact that the clock is
re-set for the death hazard for patients that progressed. Andersen and Pohar Perme18 and Andersen19 refer to this model as
homogeneous semi-Markov and to a model that depends on both 푡 and 푡 − 푡1, i. e. 훼12(푡; 푡1) = 훼12(푡; 푡 − 푡1), as semi-Markov.
Equivalently, the general model, 훼12(푡; 푡1) = 훼12(푡; 푡1), is denoted general Markov extension model11 and simply non-Markov
model15.
If the intensities are time-constant, 훼푖푗(푡) = 훼푖푗 , the model is (time-) homogeneousMarkov. Note that푋(푡) being homogeneous
Markov always implies exponential transition intensities and vice-versa, see p. 465 in Aalen et al.12 or p. 31 in Beyersmann et
al.15.
2.3 Advantages of the multistate modelling approach
In the literature, it is not uncommon that PFS and OS are modelled as arising from latent failure times20,21,8,22,23,9,24,25. Another
approach is to use copulas to capture the dependence between PFS and OS5,26,27,10,28. Neither latent times nor copulas have been
used in our general model of Section 2.1, and this is a conceptual advantage of the multistate modelling framework. To begin,
copulas are a convenient method to model general bivariate survival data, e.g., lifetimes of twins, but the structure at hand is
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more specific: Firstly, PFS is always less than or equal to OS, but copulas do not place such a restriction on the pair of event
times. This is meaningful for general bivariate survival data, but not for the ordered pair (PFS,OS). Secondly, PFS = OS with
positive probability. However, in a copula model with continuous ‘marginal’ survival functions for PFS and OS, this will happen
with probability zero only. Again, this is meaningful for general bivariate survival data, but not for (PFS,OS), where PFS = OS
simply encodes that the waiting time in the intial state equals the waiting time until the terminal state.
For discussion of the latent failure time model, assume that there are latent, non-negative random variables 퐿1 and 퐿2 such
that progression occurs, if 퐿1 < 퐿2 (and then PFS = 퐿1 and OS = 퐿2). If, however, 퐿2 ≤ 퐿1, the patient dies without prior
progression (and then OS = 퐿2). There are two problems with this approach, the first of which may appear to be the more
serious one, because it seemingly complicates estimating the correlation or the joint distribution of PFS and OS, but it really is
the second problem that stands out: Firstly, it is well known from the competing risks literature29 that one cannot tell from the
observable data whether or not 퐿1 and 퐿2 are independent. However, this problem is insolubly tied to assuming the existence of
latent times. The problem simply does not exist within the multistate framework, which is why Aalen called the non-identifiable
dependence structure of 퐿1 and 퐿2 an ‘artificial problem’30. More important is a second problem, namely whether there is
any medical insight to be gained by assuming latent times30, and we will demonstrate below that one easily expresses the joint
distribution of PFS and OS in terms of the multistate model without such a latent structure. Chiang31 summarizes the problem
by stating that the latent failure time structure requires an impossible sampling space: 퐿1 > 퐿2 implies that there is progression
after death, which is an awkward idea, to say the least.
If one assumes the additional latent failure time structure, the connection to the multistate model is as follows. Because of
the non-identifiable dependence structure of 퐿1 and 퐿2, these are typically assumed to be independent with marginal survival
functions 푃 (퐿푗 > 푡) = exp(− ∫ 푡0 훼퐿푗 (푢) d푢). It is then well known from the competing risks literature29 that 훼퐿푗 (푡) = 훼0푗(푡). Wealso have for 푡1 < 푡 that
푃 (퐿2 − 퐿1 ∈ [푡 − 푡1, 푡 − 푡1 + Δ푡) |퐿1 = 푡1, 퐿2 ≥ 푡) = 푃 (퐿2 ∈ [푡, 푡 + Δ푡) |퐿1 = 푡1, 퐿2 ≥ 푡)
= 푃 (퐿2 ∈ [푡, 푡 + Δ푡) |퐿2 ≥ 푡),
such that 훼12(푡; 푡1) = 훼퐿2(푡). Obviously, this is not a convincing property, namely that progression has no effect on the hazardof death, such that authors tend to introduce a third time, say 퐿3, conditional on 퐿1 < 퐿2 8,9, which models the residual time
until death after progression. One downside of this approach is that only 퐿1 and 퐿3 will then have a proper interpretation, but
not 퐿2. With this interpretation, we have that
푃 (퐿3 > 푣 |퐿1 < 퐿2, 퐿1 = 푡1) = 푃 (OS − PFS > 푣 |PFS = 푡1 < OS) = exp ⎛⎜⎜⎝−
푡1+푣
∫
푡1
훼12(푢; 푡1) d푢
⎞⎟⎟⎠ ,
cf. Equation (4). Again, two aspects are apparent from the above display. Firstly, the multistate framework is simpler and more
parsimonious, because it uses only two real life quantities, PFS and OS, rather than three quantities 퐿1, 퐿2 and 퐿3. Secondly,
the interpretation of 퐿3 is unclear, if 퐿1 > 퐿2. This is in contrast to the difference of OS minus PFS, which always has a proper
interpretation.
Neither the difficulties of copula modelling nor those of latent failure time modelling are present within the multistate
approach. Latent times are simply not assumed, such that neither questions of their dependence nor of their interpretation arise.
All that is modelled are the real life event times PFS and OS. Because PFS is modelled as the waiting time in the initial state
and OS is modelled as the waiting time until absorption, we naturally have both PFS ≤ OS and equality of PFS and OS with
positive probability as desired. This also contrasts the multistate approach from using copulas.
2.4 Transition probabilities and joint distribution of PFS and OS
For 푚, 푙 ∈  , abbreviate the transition probability 푃 (푋(푡) = 푚|푋(푠) = 푙, past), 푠 ≤ 푡 to be in state 푙 at time 푠 and in state
푚 at time 푡 by 푃푙푚(푠, 푡; 푡1), where the argument 푡1 is only used if the transition probability indeed depends on the time when
progression occurred. For instance, 푃12(푠, 푡; 푡1) conditions on being in state 1 at time 푠 and conditions on the fact that the 0→ 1
transition has occurred at time 푡1, 푡1 ≤ 푠.
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Standard considerations (see Aalen et al.12, Appendix A) allow to write the matrix (푃푙푚(푠, 푡))푙,푚 of transition probabilities as
a function of the transition intensities. In the IDM the upper half of this matrix has non-zero entries and these are
푃00(푠, 푡) = exp
(
−
푡
∫
푠
훼01(푢) + 훼02(푢) d푢
)
,
푃11(푠, 푡; 푡1) = exp
(
−
푡
∫
푠
훼12(푢; 푡1) d푢
)
, (5)
푃22(푠, 푡) = 1,
푃01(푠, 푡) =
푡
∫
푠
푃00(푠, 푢−)훼01(푢)푃11(푢, 푡; 푢) d푢,
푃12(푠, 푡; 푡1) = 1 − 푃11(푠, 푡; 푡1),
푃02(푠, 푡) = 1 − (푃00(푠, 푡) + 푃01(푠, 푡)). (6)
All other transition probabilities are equal to 0. These transition probabilities provide a full description of the model in
Figure 1 by only assuming existence of the intensities (1) and (2). The formulae above have interpretations: 푃00(푠, 푡) and
푃11(푠, 푡; 푡1) have the form of standard survival functions, and 푃 (PFS > 푡) = 푃00(0, 푡). For 푃01(푠, 푡) one considers the integral of
‘infinitesimal probabilities’ to move from 0 to 1 at time 푢, 푢 ∈ (푠, 푡], — the term 푃00(푠, 푢−)훼01(푢)— and to subsequently stay in
state 1 until at least time 푡— the term 푃11(푢, 푡; 푢).
The joint distribution PFS and OS in terms of the multistate process is for 푢 ≤ 푣
푃 (PFS ≤ 푢,OS ≤ 푣) = 푃 (푋(푢) ∈ {1, 2}, 푋(푣) = 2)
= 푃 (푋(푢) = 1, 푋(푣) = 2) + 푃 (푋(푢) = 2)
= 푃 (푋(푣) = 2|푋(푢) = 1) ⋅ 푃 (푋(푢) = 1|푋(0) = 0) + 푃 (푋(푢) = 2|푋(0) = 0)
= 푃 (푋(푣) = 2|푋(푢) = 1) ⋅ 푃01(0, 푢) + 푃02(0, 푢). (7)
If the process is Markov, the above formula simplifies using 푃 (푋(푣) = 2|푋(푢) = 1) = 푃12(푢, 푣), i.e. the expression does
not further depend on the time of progression 푡1 ≤ 푢. For illustration, we provide a closed formula for the joint distribution
for 푋 homogeneous Markov in Section B. For non-Markov processes, one has to integrate 푃12(푢, 푣; 푡1) over the conditional
distribution of all possible progression times 푡1 ≤ 푢, which makes the final formula somewhat tedious, see Appendix C. We
reiterate, however, that 푃 (푋(푣) = 2|푋(푢) = 1) can easily be evaluated numerically as explained in Section 2.1
Many statistics of interest can easily be derived from the joint distribution of PFS and OS, e.g. Pearson’s correlation coefficient
as in Fleischer et al.8 and Li and Zhang9. Precise formulas for these expressions based on the joint and marginal distribution as
well as further dependence measures for bivariate survival data are discussed in Chapter 4 of Hougaard11 as well as Fan et al.32.
Finally, derive the survival function 푆푂푆 for OS as
푆푂푆(푡) = 푃 (OS > 푡) = 푃00(0, 푡) + 푃01(0, 푡)
= 푆푃퐹푆(푡) + 푃01(0, 푡). (8)
Note the independence of 푆푂푆 of 푡1, which implies that the generic formula (8) is valid for the broad range of assumptions on
푋 discussed in Section 2.2. Closed formulas for the transition probabilities 푃푖푗 , 푆푃퐹푆 and 푆푂푆 for 푋(푡) a semi-Markov, time-
inhomogeneous Markov, or homogeneous Markov process and under various parametric assumptions are provided in Section A.
2.5 Correlation between PFS and OS
The joint distribution of PFS and OS together with the corresponding univariate distributions now allows to derive a formula
for the correlation between the two random variables PFS and OS. To this end, recall the general correlation formula
Corr(PFS,OS) = Cov(PFS,OS)√
Var(PFS)Var(OS)
= E(PFS ⋅ OS) − E(PFS) E(OS)√
Var(PFS)Var(OS)
. (9)
The formula above can easily be evaluated numerically using the simulation approach discussed in Section 2.1. For analytical
evaluations, mean and variance of PFS and OS can be derived via the survival functions (3) and (8). One way to compute
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E(PFS ⋅ OS) is via the distribution function of the product. In Appendix D, we show that the survival function of the random
variable PFS ⋅ OS can be written as
푃 (PFS ⋅ OS > 푡) = 푃 (PFS >
√
푡) + ∫
(0,
√
푡]
푃11(푢, 푡∕푢; 푢)푃 (PFS > 푢−)훼01(푢) d푢.
Alternatively, the expression (7) for the joint distribution function of PFS and OS can be used together with 푆푃퐹푆 , 푆푂푆 , and the
generic formula for the covariance:
Cov(푃퐹푆,푂푆) =
∞
∫
0
∞
∫
0
{푃 (PFS > 푡1,OS > 푡2) − 푃 (PFS > 푡1)푃 (OS > 푡2)} d푡1 d푡2
see e.g. p. 130 in Hougaard11.
How to estimate all the above expressions and thus the correlation from given data is discussed in Section 5.
Pearson’s correlation coefficient is regularly used in the assessment of surrogacy and as discussed in the introduction, method-
ology for this association measure has been developed in Fleischer et al.8 and Li and Zhang9. This is why here we also provide
a closed formula for this quantity, as well as an application to real data in Section 5. We would like to reiterate though that hav-
ing explicit expressions for the marginal and the joint distribution of PFS and OS allows to derive many dependence measures,
as discussed in Section 2.4.
3 THE APPROACHES OF FLEISCHER ET AL. AND OF LI AND ZHANG REVISITED AND
EXTENDED
We are now fully equipped to revisit the approaches of Fleischer et al.8 and of Li and Zhang9. These authors use latent failure
times to generate a multistate model for PFS and OS and subsequently model dependence, and specifically the correlation,
between PFS and OS. The assumption of exponentially distributed or time-constant transition hazards in Fleischer et al. implies
that their model is homogeneous Markov, see Section 2.2. Furthermore, the assumption of independent failure times in Li and
Zhang relates to a multistate model which is semi-Markov. Due to these connections of the underlying assumptions of these
approaches to those in an multistate model, we label those as Homogeneous Markov (Fleischer et al.) and Semi-Markov Weibull
(Li and Zhang) in Sections 5 and 6. In the setup of Section 2 it is now straightforward to drop the hypothetical latent times
structure and identify the transition hazards following Section 2.3. For given transition hazards, measures of dependence may
easily be evaluated using the simulation approach of Section 2.1. Alternatively, one may use the formulas in Sections 2.4 and 2.5
to derive closed expressions, but this may turn out to be somewhat tedious, see also Appendix A. For mathematical convenience,
Li and Zhang9 assume a common shape parameter in their three Weibull distributions, but this restriction can also be dropped
in our approach.
Both Fleischer et al. (exponential) and Li and Zhang (Weibull) considered parametric models, and we provide for parametric
inference using maximum likelihood methods for counting processes29,12 in Section 4. Furthermore, the IDM formulation also
allows for nonparametric estimation and inference.
Note that the IDM formulation also allows to some extent to separate the assumptions on the underlying process 푋 (time-
homogeneity andMarkovianity) and the assumption about the parametric family for the transition intensities. As a matter of fact,
assuming exponential transition intensities induces 푋 to be homogeneous Markov, but in general, the parametric assumption is
rather independent of the assumptions on 푋. For example, Weibull transition intensities can be assumed for 푋 Markov, semi-,
or non-Markov. Our chosen IDM approach allows for transparent inference based on all the various assumptions on 푋 listed in
Table A1 and for any (even transition-specific) parametric model one is willing to entertain for the transition intensities.
4 STATISTICAL INFERENCE
Maximum likelihood estimation in Fleischer et al. (exponential) and Li and Zhang (Weibull) relies on the latent failure time
structure of the their model together with a parametric assumption. The likelihood is constructed by considering the four potential
outcomes for a patient that can occur through censoring and/or events for PFS and OS. In the model entertained by Fleischer et
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al., the simplicity of the exponential distribution together with the Markov assumption would even allow to derive the parameter
estimates via dividing the number of transitions by the waiting time of all individuals for that transition.
Parametric inference in our general multistatemodel framework outlined in Section 2 relies onmaximum likelihood estimation
for counting processes29,12. In contrast to the methods used by Fleischer et al. (exponential) and Li and Zhang (Weibull), the
likelihood is based on the contributions of the three transitions in the IDM.
A general derivation of maximum likelihood estimation for parametric counting process models is e.g. given in Chapter 5
of Aalen et al.12, see also Section VII.6 of33. In general, these methods hold for a broad class of stochastic processes. In our
case, 푋 is a 3-variate counting process, where the Markov assumption is only relevant for the 1 → 2 transition. As described
in Table A1 , when parametrically modelling the transition intensities, we can explicitly account for the Markov assumption,
implying a full description of all intensities. This then allows to use the standard likelihood framework. This approach can easily
be generalized to parametric multistate models that are more general than IDMs, e.g. with more states, and the (non-)Markov
assumption can be taken into account through appropriate formulation of transition intensities.
The derivation of the likelihood for an IDM was made explicit for a parametric multistate model18 and for the example of an
extended multistate model with exponential transition intensities34.
To derive the likelihood function in the IDM considered here we follow the development in Aalen et al.12 and assume that 푛
independent multistate time-inhomogeneous Markov processes
(푋푖(푡), 0 ≤ 푡 ≤ 퐶푖; 푖 = 1,… , 푛)
are observed in continuous time. For each 푋푖 we allow for independent right-censoring at 퐶푖 ≤ 휏, with 휏 the upper time limit
of the study, see12, p. 211. The data for individual 푖 can then be represented as a multivariate counting process 푁푙푚푖, 푙, 푚 ∈ , 푙 < 푚, 푡 ≤ 퐶푖 which counts the number of the 푖-th’s individual direct transitions from 푙 to 푚 in the interval [0, 푡]. The model
is then specified, for the assumed parametric transition hazards 훼푙푚(푡) ∶= 훼푙푚(푡; 훉) depending on a parameter vector 훉, through
the intensity processes 휙푙푚푖(푡) = 푌푙푖(푡)훼푙푚(푡; 훉) with 푌푙푖(푡) = 1{푋푖(푡−) = 푙} being an at risk indicator for individual 푖. Denoting
by Δ푁푙푚푖 = 푁푙푚푖(푡) −푁푙푚푖(푡−) the increment of푁푙푚푖 at time 푡 (i.e. the number of 푖’s transitions from 푙 to 푚 at 푡), the likelihood
function for estimation of 훉 can then be written as
퐿(훉) =
푛∏
푖=1
∏
푙,푚∈ ,푙<푚
{ ∏
0<푡≤휏
휙푙푚푖(푡)Δ푁푙푚푖
}
exp
{
−
휏
∫
0
휙푙푚푖(푢) d푢
}
.
In order to obtain a maximum likelihood estimate 훉̂ of 훉 we take the logarithm of 퐿:
log퐿(훉) =
푛∑
푖=1
∑
푙,푚∈ ,푙<푚
{ ∑
0<푡≤휏
(log 훼푙푚(푡; 훉))푌푙푖(푡)Δ푁푙푚푖
}
exp
{
−
휏
∫
0
훼푙푚(푢; 훉)푌푙푖(푢) d푢
}
and maximize this function over 훉. Inference then proceeds via standard maximum likelihood theory as outlined in Aalen et
al.12, Chapter 5.
Using 훼푙푚(⋅; 훉) in the format as of Section 2, we get parameter estimates of the transition intensities and probabilities,
푆푃퐹푆 , 푆푂푆 , the correlation coefficient 퐶표푟푟(푃퐹푆,푂푆), and the joint distribution of PFS and OS.
Asymptotic covariance matrices can be evaluated based on the delta method, but we prefer bootstrapping as outlined by
Efron35 or in Bluhmki et al.36. One reason is that (co)variance formulas become increasingly tedious, another reason is that the
bootstrap is well known to work well in practice and when compared to asymptotic formulas37. Our preference for bootstrapping
is not unlike the idea of simulation in Section 2.1.
Another advantage of our multistate formulation of the IDM is that it also allows for non-parametric estimation of all the
quantities of interest. To this end, recall that 훼푙푚(푡) d푡 is the infinitesimal conditional transition probability for an individual to
be in state 푙 just prior to 푡 and transitioning to 푚 in the interval [푡, 푡 + d푡). If we observe a transition from 푙 to 푚 for at least
one individual 푖 we estimate the above probability through the ratio of the sum of increments ∑푛푖=1Δ푁푙푚푖(푡) divided by thetotal number of individuals at risk of the transition out of 푙 just prior to 푡. Summing these quantities up yields the Nelson-Aalen
estimator of the cumulative transition hazards, for 푙 < 푚, in a time-inhomogeneous Markov IDM:
퐴̂푙푚(푡) =
∑
푠≤푡
∑푛
푖=1Δ푁푙푚푖(푠)∑푛
푖=1 푌푙푖(푠)
.
Violations of the Markov property only affect 퐴̂12(푡), which would then be estimating an only partly conditional cumulative
transition rate, i.e., a mixture of the individual transition hazards38. Based on the corresponding multivariate Nelson-Aalen39
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estimator for the matrix of cumulative transition intensities, the Aalen-Johansen40 estimator of all the transition probabilities
in Section 2.4 can easily be derived. For a Markov IDM, Section 3.4.2 in Aalen et al.12 provides closed formulas for estimates
of these probabilities. Plugging in these estimates in the formulas for 푆푃퐹푆 , 푆푂푆 , the joint distribution of PFS and OS, and
퐶표푟푟(푃퐹푆,푂푆) allows for nonparametric estimation of all these quantities in the IDM framework, either in a Markov setting
or, using the approach of Putter and Spitoni41, in a non-Markov IDM. However, as is common in time-to-event outcomes with
right-censoring, estimates of survival functions for PFS and OS generally do not drop down to zero, implying that not the entire
distributions of PFS and OS can be identified nonparametrically. As a consequence, parametric extrapolation would be required
to estimate these functions and quantities derived from them, specifically the correlation coefficient for PFS and OS.
Despite this limitation, nonparametric estimation provides a valuable tool to check the goodness of fit of an assumed
parametric model12.
Note that the formulas in Section 2.4 are also valid if푋 is non-Markov, so that plugging in estimates of transition probabilities
that account for the non-Markovianity yields valid estimates of the above quantities for 푋 non-Markov. Such estimates are e.g.
discussed in Meira et al.42.
In our approach, we assume that the date of progression is when it is diagnosed. Often, in trials assessing PFS assessments
happen at regular intervals. How to account for that type of measurements in the likelihood is discussed by Zeng et al.43.
5 SIMULATION RESULTS FOR CORRELATION COEFFICIENT
Section 2.5 provides formulas that can be used to compute Pearson’s correlation coefficient from given data, either through
plugging in estimates of 푆푃퐹푆 and 푆푂푆 and integrating numerically (or even analytically in specific situations) or through
simulation.
In Figure 2 we show estimated correlation coefficients from 1000 simulated trials, comparing a homogeneous Markov and
Semi-Markov Weibull model to our proposed approach. For the technical details of the first two we refer to Fleischer et al.8 and
Li and Zhang9. In our approach we assume an inhomogeneous Markov model with Weibull transition hazards, labelled (Time-)
Imhomogeneous Markov Weibull in what follows.
The assumptions for the simulations were as follows: For 500 sampled patients, transition intensities were assumed to follow a
time-inhomogeneousMarkov illness-deathmodel as described in Section 2.1, withWeibull transition intensities as in Table A2 .
The parameters were chosen as 훾01 = 1.5 and 휆01 = 0.57 for the first transition, resulting into a medium hazard of progression
which increases over time. With 훾02 = 0.5 and 휆02 = 0.065, the hazard for death without progression is much lower than the
one for progression. As a consequence, on average only about seven percent of patients die without a prior progression. Finally,
values of 훾12 = 0.85 and 휆12 = 1.1 imply a high initial transition hazard from progression to death, but 훼12 decreases over time
with the made assumptions, where in this time-inhomogeneous model time is measured from the origin. All this entails that
PFS and OS times are generally not too different, meaning that estimated correlation coefficients are relatively high.
Comparing the three estimates of the correlation coefficient in Figure 2 , the models based on the homogeneous Markov8
and semi-Markov9 assumption seem not well able to capture that with our choice of the parameters of 훼12 the hazard to die
after progression is lower the later the progression occurs. As a consequence, both these models are overestimating the true
underlying correlation.
More results for alternative assumptions on the underlying transition hazards are provided in a web supplement.
6 REAL DATA EXAMPLE
To illustrate the proposed methodology, we applied it to the data of CLEOPATRA44, a large Phase 3 randomized clinical trial
in HER2-positive metastatic breast cancer. In the trial, 808 patients were randomized. At the primary analysis with a clinical
cutoff date of 13th May 2011, the key secondary endpoint investigator-assessed PFS (Inv-PFS) gave an estimated hazard ratio
of 0.65 ([0.54, 0.78]). For OS, the hazard ratio was 0.64 ([0.47, 0.88]). After an additional interim analysis for OS with clinical
cutoff date 14th May 2012, cross-over from the control to the treatment arm was allowed, and about 12% of the patients initially
randomized to the control arm actually crossed over. Using a clinical cutoff of 11th February 2014 for the final analysis on OS,
the estimated hazard ratios for Inv-PFS and OS were updated to 0.68 ([0.58, 0.80], based on 604 events) and 0.68 ([0.56, 0.84],
389 deaths), respectively45. In what follows, we analyze the data from this last snapshot.
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FIGURE 2 Estimated correlation coefficients for Weibull transition intensities (transition-specific shape parameter), time-
inhomogeneous Markov process, 1000 simulation runs. The horizontal line corresponds to the true correlation, received by
plugging in the parametric assumption in the correlation formula in Section 2.5.
As for the number of transitions, we observe 579 transitions 0 → 1, 47 from 0→ 2, and 342 from 1 → 2.
6.1 Cumulative hazards
As a first illustration, in Figure 3 we provide estimates for the cumulative hazard functions for each transition, under various
assumptions, and for all CLEOPATRA patients jointly. The two plots in the upper row and the left-most bottom row plots provide
different estimates for the cumulative hazards for each transition in the IDM depicted in Figure 1 : the entirely nonparametric
Nelson-Aalen estimate, the two homogeneous Markov and semi-Markov parametric estimates assuming an exponential8 or
Weibull9 model and our time-inhomogeneous Markov approach based on the counting process likelihood developed in this
paper. For the 0 → 1 transition all models provide a very similar and satisfactory fit. For the 0 → 2 transition we find that the
added flexibility of a model with twomore shape parameters provides a better fit, as judged by visually comparing the parametric
to the nonparametric estimate. As for the 1→ 2 transition, we provide two graphs, accounting for the different time-scale of the
various models. In the lower-left plot, the time-inhomogeneous Markov model seems to slightly overestimate the cumulative
hazard of that transition, likely induced by the shape of the cumulative hazard function of the chosenWeibull distribution, which
is an non-decreasing function through the origin. The estimates based on the homogeneous Markov and semi-Markov models
by Fleischer et al. and Li and Zhang are depicted in the lower-right plot, with 푥-axis time scale time since progression.
6.2 Survival functions
Figure 4 depicts estimates of survival functions for PFS and OS, based on plugging in estimates of cumulative hazards into
the formulas for the transition probabilities and plugging these in in turn into the expressions for 푆푃퐹푆 and 푆푂푆 . One of the
questions that has been explored based on an IDM is to quantify the association between PFS and OS through estimation of
Pearson’s correlation coefficient8,9. In order to see whether that association is different between control and treatment arm
in CLEOPATRA, we split the plot by treatment arms. In general, judging goodness-of-fit of the parametric models through
comparison with the nonparametric Kaplan-Meier estimate, we find that generally PFS is very similar for all the methods and
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FIGURE 3 CLEOPATRA trial: estimates for cumulative hazards for each transition.
in both treatment arms. This is not surprising, for the following reasons: first, the estimates of the cumulative hazard for the
0 → 1 transition are very similar for the different methods. Second, the difference in estimates for the 0 → 2 transition does
not relevantly influence 푆푃퐹푆 as the number of such transitions is relatively much lower compared to the number of 0 → 1
transitions. Finally, since 푆푃퐹푆 in (3) only depends on the hazards of the 0→ 1, 2 transitions it is agnostic to whether we assume
a semi-Markov or Markovian model. Thus, similar estimates for 푆푃퐹푆 are expected unless the estimated shape parameter of the
Weibull model with restricted shape parameter9 for the 0→ 1 transition differs relevantly from the one for our IM model.
The three methods also yield similar estimates for OS, which makes the differences seen in the goodness-of-fit in Figure 3
appear less important. One possible reason for this will be that PFS = OS with positive probability.
6.3 Inference for the correlation coefficient between PFS and OS
One important aspect when validating PFS as a potential surrogate endpoint for OS is to analyze their correlation8,9. Fleischer
et al. discuss that if the correlation is rather low it might not be reasonable to pursue a joint modelling of PFS and OS but
to consider the two endpoints separately. According to the latter authors, even more important is the comparison of different
correlation values for different substances, lines of treatment or indications. Examples for non-small cell lung cancer (NSCLC)8
and prostate as well as larynx cancer9 have been used to illustrate the methodology. Estimated correlations between PFS and
OS range from 0.34 for a NSCLC example based on 95 patients in Fleischer et al. to 0.90 in an example based on 356 patients
in Li and Zhang.
The estimated correlation coefficients for the CLEOPATRA trial in HER2-positive metastatic breast cancer are provided in
Table 1 . It is important to note that our proposed methods also allow to provide confidence intervals for these correlation
coefficients. We find that irrespective of the method, the correlation between PFS and OS is lower in the control compared
to the treatment arm. A potential reason for this is that after the primary analysis for PFS, crossover from the control to the
treatment arm was allowed, potentially confounding the association between PFS and OS in the control arm. As for the various
assumptions on 푋 and the parametric transition intensities, estimates for the correlation coefficient are rather comparable and
likely not relevantly different taking into account estimation uncertainty. CLEOPATRA is quite a large trial, with 808 patients,
604 PFS and 389 OS events providing substantial information on PFS and OS. Still, confidence intervals around correlation
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FIGURE 4 CLEOPATRA trial: various estimates of survival functions for OS (upper curves) and PFS (lower curves).
coefficients have a width of up to 0.15 for the homogeneous Markov and the semi-Markov model (with the latter based on the
same shape parameter for all transition intensities) and are even wider for the time-inhomogeneous Markov model with Weibull
transition hazards. So, it seems precisely estimating the correlation coefficient is inherently a hard task even for this quite large
dataset, and the precision crucially depends on the bias-variance trade-off taken, i.e. whether a more or less restrictive parametric
model is entertained. Note that since neither for PFS nor OS the Kaplan-Meier estimate drop down to zero, we are not able to
fully nonparametrically estimate the correlation coefficient.
On an absolute scale, the correlation coefficients estimated for CLEOPATRA under different model assumptions are
comparable to those Li and Zhang9.
Control arm Treatment arm
Homogeneous Markov (Fleischer et. al) 0.543 [0.480; 0.609] 0.641 [0.571; 0.709]
Semi-Markov Weibull (Li and Zhang) 0.552 [0.489; 0.615] 0.644 [0.572; 0.718]
Time-inhomogeneous Markov Weibull 0.532 [0.434; 0.631] 0.567 [0.434; 0.680]
TABLE 1 CLEOPATRA trial: Estimated correlation coefficients between PFS and OS, including 95% confidence intervals
based on 1000 bootstrap samples.
7 DISCUSSION
We have suggested multistate modelling to jointly model occurrence of PFS and OS. The multistate framework improves on
the commonly used latent times20,21,8,22,23,9,24,25 or copulas5,26,27,10,28 in that it is the most parsimonious model. It works without
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hypothetical constructions while ensuring the natural properties that PFS ≤ OS and that equality holds with positive proba-
bility. We have demonstrated that the joint distribution of PFS and OS can be derived based on a multistate model. No further
assumptions were required. The multistate model was allowed to be non-Markov, and we have only assumed that the model is
sufficiently smooth in that the transition intensities exist. For illustration, we have demonstrated how to express the correlation
between PFS and OS, which has received some attention recently8,9. We have improved on these approaches by fitting them
into our general framework and providing methods of statistical inference. The methods were then illustrated using data from a
recent large randomized clinical trial.
The real data example also illustrated restrictions of using the correlation coefficient to quantify the dependence between
PFS and OS. Firstly, and as is common in time-to-event outcomes, the Kaplan-Meier curves did not drop down to zero for PFS
and OS. The implication is that not the entire distributions of PFS and OS can be identified nonparametrically, and this is in
particular true for OS. As a consequence, parametric extrapolation would be required if one wanted to estimate the correlation
coefficient based on these nonparametric estimates. Secondly, and almost irrespective of the goodness of the parametric fit, the
main message from estimating the correlation was that the higher PFS, the higher OS. But this is, of course, no surprise, because
PFS ≤ OS.
Our approach allows for any parametric specification of the transition intensities, generalizing the use of constant hazards8 or
Weibull9 hazards with common shape parameter. If goodness of fit is a concern, the transition probabilities of Section 2.4 can be
estimated nonparametrically, either in a time-inhomogeneous Markov model12 or, provided that censoring is entirely random,
even in a non-Markov model41. However, this is only possible on the time interval of follow-up. If a (partially) nonparametrical
analysis is desired, on would then need to parametrically model the remainder of the multistate distribution, again relying on
extrapolation. An alternative would be to evaluate the integrals in Section 2.5 only up to the last observed event time, similar
to the concept of restricted mean survival, but usefulness of such a restricted dependence measure would need to be further
investigated. These issues call for further investigating how to adequately study the dependence between PFS and OS. We
reiterate that whatever the choice of such a dependence measure may be, it would be a function of the joint distribution of PFS
and OS and could hence be studied within our framework.
8 ACKNOWLEDGMENTS
This paper summarizes and extends the results of the first author’s MSc thesis submitted at the University of Ulm. Part of the
research for the thesis was conducted while the first author was still an intern in the Biostatistics Department of Hoffmann-La
Roche in Basel. JB was partially supported by grant BE 4500/1-2 of the German Research Foundation (DFG).
How to cite this article: Meller M, Beyersmann J, and Rufibach K (xxxx), Joint modelling of progression-free and overall
survival and computation of correlation measures, Stat Med, xxxx;xx:x–x.
APPENDIX
A CLOSED FORMULAS FOR TRANSITION PROBABILITIES AND FOR 푆푃퐹푆 AND 푆푂푆
In this section, we provide closed formulas for the transition probabilities 푃푖푗 and survival functions for PFS and OS for
푋(푡) a semi-Markov, time-inhomogeneous Markov, and homogeneous Markov process. The non-Markov case requires further
assumptions on how transition intensities depend on 푡1, and we will not pursue this further here.
As discussed in Section 2, in the case of 푋(푡) being homogeneous Markov then the transition intensities are constant in time
since origin (and independent of 푡1) and thus exponential. Reversely put, if we assume “homogeneous” (i.e. 훼푖푗 independent of
푡 and 푡1) exponentially distributed transition intensities, then the homogeneous and time-inhomogeneous Markov as well as the
semi-Markov model all coincide. If we allow 훼12 to depend on 푡1 then a more general non-Markov, or Markov extension in the
terminology of Hougaard11, assumption for 푋(푡) has to be entertained.
Fleischer et al.8 (exponential) and Li and Zhang9 (Weibull) assumed parametric models in a latent failure time model for the
modelling of PFS and OS. As much as possible at all, we compare our results from a multistate model for 푆푃퐹푆 and 푆푂푆 to
what they received.
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Table A1 provides general formulas for transition probabilities under the various assumptions on 푋(푡).
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A.1 Exponential (time-constant) transition hazards
As for the homogeneous Markov or exponential case, we assume that the transition hazards in our multistate model in Figure 1
are constant and independent of 푡1:
훼01(푡) = 휆01, 훼02(푡) = 휆02, 훼12(푡; 푡1) = 휆12.
Then, abbreviating 휆012 ∶= 휆12 − 휆01 − 휆02,
푃 TH00 (푠, 푡) = exp
(
−
푡
∫
푠
휆01 + 휆02 d푢
)
= exp
(
−(휆01 + 휆02)(푡 − 푠)
)
,
푃 TH11 (푠, 푡) = exp
(
−
푡
∫
푠
휆12 d푢
)
= exp
(
−휆12(푡 − 푠)
)
,
푃 TH01 (푠, 푡) =
푡
∫
푠
푃 TH00 (푠, 푢−)휆01푃
TH
11 (푢, 푡) d푢 = 휆01
푡
∫
푠
exp
(
−(휆01 + 휆02)(푢− − 푠)
)
exp
(
−휆12(푡 − 푢)
)
d푢
= 휆01 exp
(
(휆01 + 휆02)푠 − 휆12푡
) 푡
∫
푠
exp(휆012푢) d푢
= 휆01휆−1012
[
exp
(
−(휆01 + 휆02)(푡 − 푠)
)
− exp
(
−휆12(푡 − 푠)
)]
.
We note that all these quantities depend on the interval limits 푠 and 푡 only through the difference 푡 − 푠, as is expected for a
time-homogeneous Markov model.
Plugging the expressions from Table A1 in (3) and (8) we get
푆TH푃퐹푆(푡) = 푃
TH
00 (0, 푡) = exp
(
−(휆01 + 휆02)푡
)
and
푆TH푂푆(푡) = 푆
TH
푃퐹푆(푡) + 푃
TH
01 (0, 푡) =
휆12 − 휆02
휆012
exp
(
−(휆01 + 휆02)푡
)
+
휆01
휆012
exp(−훼12푡).
Comparing 푆TH푃퐹푆 and 푆TH푂푆 to those in Theorem 5 in Fleischer et al.8 we find that these formulas are identical to those derivedusing the latent failure time assumption.
A.2 Weibull transition hazards
If a Weibull model should be entertained for the transition hazards, then we can either specify a time-inhomogeneous Markov
or semi-Markov model as in Table A2 .
훼01 훼02 훼12
time-inhomogeneous Markov
훼01(푡) = 휆01 ⋅ 훾01푡훾01−1 훼02(푡) = 휆02 ⋅ 훾02푡훾02−1
훼12(푡) = 휆12 ⋅ 훾12푡훾12−1
semi-Markov 훼12(푡; 푡1) = 휆12 ⋅ 훾12(푡 − 푡1)훾12−1
TABLE A2 Weibull transition intensities.
Note that using the multistate formulation, Weibull intensities with transition-specific shape parameters can be used, no
restriction to a common shape parameter as in Li and Zhang9 is needed to be able to derive closed formulas.
For the time-inhomogeneous model, plugging in into (3) and (8) yields, after some straightforward algebraic manipulations,
푆TI푃퐹푆(푡) = 푃
SM
00 (0, 푡) = exp(−휆01푡
훾01 − 휆02푡훾02)
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and
푆TI푂푆(푡) = 푆
TI
푃퐹푆(푡) + 푃
TI
01 (0, 푡)
= 푆TI푃퐹푆(푡) + 휆01훾01
푡
∫
0
푢훾01−1 ⋅ exp
(
−휆01푢훾01 − 휆02푢훾02 − 휆12(푡훾12 − 푢훾12)
)
d푢
for the survival function for OS. As for the semi-Markov model, the hazard 훼12 = 훼12(푡; 푡1) for the transition from PD to death
not only depends on the actual time 푡, but also on the time 푡1 of the transition out of the initial state. Similar manipulations yield
푆SM푃퐹푆 = 푆
TI
푃퐹푆 for the survival function for PFS and
푆SM푂푆 (푡) = 푆
SM
푃퐹푆(푡) + 푃
SM
01 (0, 푡)
= 푆SM푃퐹푆(푡) + 휆01훾01
푡
∫
0
푢훾01−1 ⋅ exp
(
−휆01푢훾01 − 휆02푢훾02 − 휆12(푡 − 푢)훾12
)
d푢
for the survival function for OS. Now, how do these expressions compare to those derived under a latent failure time assumption
in Li and Zhang9 when setting 훾 ∶= 훾01 = 훾02 = 훾12? The survival function 푆TI푃퐹푆 = 푆SM푃퐹푆 for PFS simplifies to that in thelatter paper as does 푆SM푂푆 . We would like to emphasize that the fact that the latent failure time and multistate model formulationlead to the same expressions for the semi-Markov case does not imply that the assumptions on 푋(푡) are identical for the latent
failure time and the multistate model.
To conclude this section we note that (3) and (8) are general formulas based on the IDM. Closed formulas for other parametric
models can easily be derived from these.
B JOINT DISTRIBUTION OF PFS AND OS IF 푋 IS MARKOV
Equation (7) provides the expression of the joint distribution of PFS and OS for a general, not necessarily Markov, process 푋.
If we assume 푋 to be Markov, then 푃12(푢, 푣; 푡1) simplifies to 푃12(푢, 푣) so that we can write (7) as
푃 (PFS ≤ 푢,OS ≤ 푣) = 1 − 푃00(0, 푢) − 푃01(0, 푢)푃11(푢, 푣).
More specifically, if 푋 is homogeneous Markov we can plug in the formulas derived in Section A.1 to get
푃 (PFS ≤ 푢,OS ≤ 푣) = 1 − 휆01휆−1012 exp(−휆12푣) + exp(−휆012푢)
(
휆01휆
−1
012 exp(−휆12푣) − exp(−휆12푢)
)
.
Corresponding formulas for alternative assumptions on 푋 can be derived analogously.
C JOINT DISTRIBUTION OF PFS AND OS IF 푋 IS NON-MARKOV
Here, we provide the general expression for the joint distribution of PFS and OS if 푋 is non-Markov. To this end, we need to
evaluate 푃 (푋(푣) = 2|푋(푢) = 1) under that assumption. The following computations are repeatedly using the formula of total
probability and conditioning. Assuming 푢 ≤ 푣 we have
푃 (푋(푣) = 2|푋(푢) = 1) = 푢∫
0
푃 (푋(푣) = 2|푋(푢) = 1,PFS = 푡1) d푃 (PFS ≤ 푡1|푋(푢) = 1)
=
푢
∫
0
푃12(푢, 푣; 푡1) d푃 (PFS ≤ 푡1|푋(푢) = 1). (C1)
In C1, integration is w.r.t. 푡1 and over the time interval (0, 푢]. Now, for 푡1 ≤ 푢, we have that
푃 (PFS ≤ 푡1|푋(푢) = 1) = 푃 (푋(푡1) ∈ {1, 2}|푋(푢) = 1)
= 푃 (푋(푡1) = 1|푋(푢) = 1) (C2)
= 푃 (푋(푡1) = 1, 푋(푢) = 1)∕푃 (푋(푢) = 1)
= 푃 (푋(푡1) = 1, 푋(푢) = 1)∕푃01(0, 푢), (C3)
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where (C2) follows, because given the process is still in the intermediate state at 푢, 푢 ≥ 푡1, 푋(푡1) = 2 is impossible. As for the
nominator,
푃 (푋(푡1) = 1, 푋(푢) = 1) =
푡1
∫
0
푃 (푋(푡1) = 1, 푋(푢) = 1|PFS = 푠) d푃 (PFS ≤ 푠)
=
푡1
∫
0
푃 (푋(푢) = 1|푋(푡1) = 1,PFS = 푠)푃 (푋(푡1) = 1|PFS = 푠) d푃 (PFS ≤ 푠)
=
푡1
∫
0
푃11(푡1, 푢; 푠)푃 (푋(푡1) = 1|PFS = 푠) d푃 (PFS ≤ 푠) by (5).
It remains to derive 푃 (푋(푡1) = 1|PFS = 푠) for 푠 ∈ (0, 푡1]. To this end,
푃11(푠, 푡1; 푠) = 푃 (푋(푡1) = 1|푋(푠) = 1,PFS = 푠)
= 푃 (푋(푡1) = 1, 푋(푠) = 1|PFS = 푠)∕푃 (푋(푠) = 1|PFS = 푠)
= 푃 (푋(푡1) = 1|PFS = 푠)∕푃 (푋(푠) = 1|PFS = 푠)
because the event {푋(푠) = 1} is implied by the condition {PFS = 푠} together with noting that 푋 is still in state 1 at 푡1, 푡1 ≥ 푠.
Now, the denominator in the last display is
푃 (푋(푠) = 1|PFS = 푠) = 푃 (푋(PFS) = 1|PFS = 푠) = 훼01(푠)
훼01(푠) + 훼02(푠)
,
see our discussion on how to simulate PFS-OS trajectories in Section 2.1. Rearranging gives
푃 (푋(푡1) = 1|PFS = 푠) = 훼01(푠)훼01(푠) + 훼02(푠)푃11(푠, 푡1; 푠).
The last display has an interpretation: Conditional on PFS at time 푠 one is in the progression state at a later time 푡1, if, firstly, one
actually moves into the progression state at the time of PFS. Given a transition into the progression state at this time, secondly,
one has to remain in the intermediate state of the model until time 푡1. Putting everything together, we thus have
푃 (PFS ≤ 푡1|푋(푢) = 1) = 푃01(0, 푢)−1 푡1∫
0
푃11(푡1, 푢; 푠)푃11(푠, 푡1; 푠)
훼01(푠)
훼01(푠) + 훼02(푠)
d푃 (PFS ≤ 푠).
Plugging this distribution function into (C1) finally allows to compute 푃 (푋(푣) = 2|푋(푢) = 1) under a non-Markov assumption.
We reiterate that our simulation approach in Section 2.1 may be a convenient alternative to evaluating these somewhat tedious
formulas.
D DISTRIBUTION FUNCTION OF PFS ⋅ OS
We have that
푃 (PFS ⋅ OS > 푡) = 푃 (PFS >
√
푡) + 푃 (PFS ≤√푡,PFS ⋅ OS > 푡).
When PFS ≤√푡,PFS ⋅ OS > 푡 is only possible, if 푋(PFS) = 1. Hence, we can express the last probability as
푃 (PFS ≤√푡,PFS ⋅ OS > 푡) = ∫ 푃 (PFS ≤√푡,PFS ⋅ OS > 푡 |PFS = 푢,푋(PFS) = 1) d푃 (PFS ≤ 푢,푋(PFS) = 1)
= ∫
(0,
√
푡]
푃 (OS > 푡∕푢 |PFS = 푢,푋(PFS) = 1) d푃 (PFS ≤ 푢,푋(PFS) = 1)
= ∫
(0,
√
푡]
푃11(푢, 푡∕푢; 푢) d푃 (PFS ≤ 푢,푋(PFS) = 1).
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It remains to compute 푃 (PFS ≤ 푢,푋(PFS) = 1), but this is nothing else than the cumulative incidence function of a competing
risk, i.e. the expected proportion of individuals experiencing progression over the course of time. It can be computed according
to
푃 (PFS ≤ 푢,푋(PFS) = 1) =
푢
∫
0
푃 (PFS > 푠−)훼01(푠) d푠
=
푢
∫
0
푆푃퐹푆(푠−)훼01(푠) d푠,
see e.g. Equation (3.11) in Beyersmann et al.15.
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1 ESTIMATION OF AND INFERENCE FOR THE CORRELATION COEFFICIENT -
FURTHER SIMULATION SCENARIOS
Section 5 of Meller et. al1 presents estimated correlation coefficients from 1000 simulated studies following a time-
inhomogeneousMarkovmodel withWeibull transition intensities, where the results using the approaches of2 and3 are compared
with the results using a time-inhomogeneous Markov approach based on a counting process likelihood described in Andersen
and Keiding4. In Figures 1 - 4 estimated correlation coefficients from 1000 simulated studies for further four simulation
scenarios applying the three different approaches are provided.
Like in Section 5 of Meller et al.1, the assumptions in each of the four scenarios for the simulations were as follows: 500
patients were sampled for each scenario and for simplicity reasons no censoring was applied. The underlying model assumption
on the illness-death model for each scenario is provided in the first column of Table 1 and the distribution and parameter of
the transition intensities in the rest of the table.
Model Assumption Distribution 훾01 휆01 훾02 휆02 훾12 휆12
Homogeneous Markov Exponential * - 0.6 - 0.075 - 0.9
Semi-Markov Weibull 1.5 0.6 1.5 0.1 1.5 0.4
Semi-Markov Weibull 1.8 0.3 0.5 0.05 1.2 1
Time-inhomogeneous Markov Weibull 1.3 0.85 1.3 0.1 1.3 0.3
TABLE 1 Model assumption, distribution and true parameter values of transition intensities for each scenario. 훾푖푗 and 휆푖푗
correspond to the scale and shape parameter of a Weibull distribution.
* Transition intensities in a (time-) homogeneous Markov model are by definition exponentially distributed.
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FIGURE 1 Estimated correlation coefficients for time-constant (exponential) transition intensities, (time-)homogeneous
Markov process, 1000 simulation runs.
As expected for a scenario with an underlying time-homogeneousMarkov process and resulting time-constant tranisiton inten-
sities, all three approaches, the approaches of Fleischer et al.2, Li and Zhang3 and Meller et al.1, result in unbiased estimation
of the correlation between PFS and OS (Figure 1 ).
Once the illness-death models follows a semi-Markov process, the Inhomogenous Markov Weibull approach of Meller et al.1
results into biased estimation of the correlation coefficient (Figure 2 and 3 ). However, if the semi-Markov assumptions seems
plausible in a particular application, the flexibility of the approach would allow for an unbiased estimation of the correlation
between PFS and OS by plugging in transition intensites for semi-Markov models shown in the Appendix of Meller et al.1 into
the formulae of Section 2.
Figure 4 provides the results of another scenario where the Inhomogeneous Markov Weibull approach yields to unbiased
estimation of the correlation coefficient. Despite the shared shape parameter of the Weibull transition hazards, the approach of
Li and Zhang3 does result into biased estimation and is, in contrary to the approach described in Meller et al.1, not adaptable to
alternative assumptions.
2 REAL DATA EXAMPLE - CUMULATIVE HAZARDS PER TREATMENT ARM
Figure 3 of Meller et al.1 illustrates estimates of the cumulative hazard function, using the same three approaches applied to the
simulated studies in 1, for each transition in the CLEOPATRA study5 for all patients jointly. Figure 5 and Figure 6 provide
the estimated cumulative incidence functions separated by treatment arm.
Meller ET AL 3
FIGURE 2 Estimated correlation coefficients for Weibull transition intensities (equal shape parameter), semi-Markov process,
1000 simulation runs.
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FIGURE 3 Estimated correlation coefficients for Weibull transition intensities (transition-specific shape parameter), semi-
Markov process, 1000 simulation runs.
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FIGURE 4 Estimated correlation coefficients for Weibull transition intensities (equal shape parameter), time-inhomogeneous
Markov process, 1000 simulation runs.
FIGURE 5 CLEOPATRA trial: estimates for cumulative hazards for each transition for the treatment arm.
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FIGURE 6 CLEOPATRA trial: estimates for cumulative hazards for each transition for the control arm.
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